Quintiles has entered into a strategic alliance with Movetis NV for the commercialization of its new product, Resolor (prucalopride), in the U.K. and Germany. Under the alliance, Quintiles will be responsible for commercialization, consulting, marketing services, regulatory and post-marketing pharmacovigilance. Movetis is a European specialty pharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of gastrointestinal diseases. Movetis obta...